Search

Your search keyword '"Finke, Christy"' showing total 22 results
Start Over Author "Finke, Christy" Journal leukemia
22 results on '"Finke, Christy"'

5. Spectrum of abnormalities and clonal transformation in germline RUNX1 familial platelet disorder and a genomic comparative analysis with somatic RUNX1 mutations in MDS/MPN overlap neoplasms

Author

DiFilippo, Emma C., Coltro, Giacomo, Carr, Ryan M., Mangaonkar, Abhishek A., Binder, Moritz, Khan, Shakila P., Rodriguez, Vilmarie, Gangat, Naseema, Wolanskyj, Alexandra, Pruthi, Rajiv K., Chen, Dong, He, Rong, Viswanatha, David S., Lasho, Terra, Finke, Christy, Tefferi, Ayalew, Pardanani, Animesh, and Patnaik, Mrinal M.

Published
2020
Full Text
View/download PDF

6. Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)—a study of 1084 patients

Author

Coltro, Giacomo, Mangaonkar, Abhishek A., Lasho, Terra L., Finke, Christy M., Pophali, Prateek, Carr, Ryan, Gangat, Naseema, Binder, Moritz, Pardanani, Animesh, Fernandez-Zapico, Martin, Robertson, Keith D., Bosi, Alberto, Droin, Nathalie, Vannucchi, Alessandro M., Tefferi, Ayalew, Hunter, Anthony, Padron, Eric, Solary, Eric, and Patnaik, Mrinal M.

Published
2020
Full Text
View/download PDF

7. Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients

Author

Mangaonkar, Abhishek A., Swoboda, David M., Coltro, Giacomo, Lasho, Terra L., Novotny, Paul J., Pophali, Prateek, Carr, Ryan M., Binder, Moritz, Finke, Christy M., Gangat, Naseema, Al-Kali, Aref, Begna, Kebede H., Reichard, Kaaren K., Ketterling, Rhett P., Al Ali, Najla H., Vafaii, Pardis, Zhang, Ling, Padron, Eric, Talati, Chetasi, and Patnaik, Mrinal M.

Published
2020
Full Text
View/download PDF

14. Landscape of RAS pathway mutations in patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a study of 461 molecularly annotated patients

Author

Buradkar, Ajinkya, primary, Bezerra, Evandro, additional, Coltro, Giacomo, additional, Lasho, Terra L., additional, Finke, Christy M., additional, Gangat, Naseema, additional, Carr, Ryan M., additional, Binder, Moritz, additional, Mangaonkar, Abhishek A., additional, Ketterling, Rhett, additional, Khan, Shakila, additional, Rodriguez, Vilmarie, additional, Tefferi, Ayalew, additional, and Patnaik, Mrinal M., additional

Published
2020
Full Text
View/download PDF

16. Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)—a study of 1084 patients

Author

Coltro, Giacomo, primary, Mangaonkar, Abhishek A., additional, Lasho, Terra L., additional, Finke, Christy M., additional, Pophali, Prateek, additional, Carr, Ryan, additional, Gangat, Naseema, additional, Binder, Moritz, additional, Pardanani, Animesh, additional, Fernandez-Zapico, Martin, additional, Robertson, Keith D., additional, Bosi, Alberto, additional, Droin, Nathalie, additional, Vannucchi, Alessandro M., additional, Tefferi, Ayalew, additional, Hunter, Anthony, additional, Padron, Eric, additional, Solary, Eric, additional, and Patnaik, Mrinal M., additional

Published
2019
Full Text
View/download PDF

17. Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients

Author

Mangaonkar, Abhishek A., primary, Swoboda, David M., additional, Coltro, Giacomo, additional, Lasho, Terra L., additional, Novotny, Paul J., additional, Pophali, Prateek, additional, Carr, Ryan M., additional, Binder, Moritz, additional, Finke, Christy M., additional, Gangat, Naseema, additional, Al-Kali, Aref, additional, Begna, Kebede H., additional, Reichard, Kaaren K., additional, Ketterling, Rhett P., additional, Al Ali, Najla H., additional, Vafaii, Pardis, additional, Zhang, Ling, additional, Padron, Eric, additional, Talati, Chetasi, additional, and Patnaik, Mrinal M., additional

Published
2019
Full Text
View/download PDF

19. Spectrum of abnormalities and clonal transformation in germline RUNX1familial platelet disorder and a genomic comparative analysis with somatic RUNX1mutations in MDS/MPN overlap neoplasms

Author

DiFilippo, Emma C., Coltro, Giacomo, Carr, Ryan M., Mangaonkar, Abhishek A., Binder, Moritz, Khan, Shakila P., Rodriguez, Vilmarie, Gangat, Naseema, Wolanskyj, Alexandra, Pruthi, Rajiv K., Chen, Dong, He, Rong, Viswanatha, David S., Lasho, Terra, Finke, Christy, Tefferi, Ayalew, Pardanani, Animesh, and Patnaik, Mrinal M.

Published
2020
Full Text
View/download PDF

20. Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2mutations in chronic myelomonocytic leukemia (CMML)—a study of 1084 patients

Author

Coltro, Giacomo, Mangaonkar, Abhishek A., Lasho, Terra L., Finke, Christy M., Pophali, Prateek, Carr, Ryan, Gangat, Naseema, Binder, Moritz, Pardanani, Animesh, Fernandez-Zapico, Martin, Robertson, Keith D., Bosi, Alberto, Droin, Nathalie, Vannucchi, Alessandro M., Tefferi, Ayalew, Hunter, Anthony, Padron, Eric, Solary, Eric, and Patnaik, Mrinal M.

Abstract

Loss-of-function TET2mutations (TET2MT) are frequent early clonal events in myeloid neoplasms and are thought to confer a fitness advantage to hematopoietic precursors. This large, multi-institutional study (n= 1084), investigated the TET2mutational landscape and prognostic implications of the number, type, and location of TET2MTand the epistatic relationship with other somatic events in chronic myelomonocytic leukemia (CMML). Nine hundred and forty-two TET2MTwere identified in 604 (56%) patients, of which 710 (75%) were predicted to be truncating (involving the catalytic domain). Three hundred and sixteen (29%) patients had ≥1 TET2MT, with 28%, 1%, and 0.2% harboring 2, 3, and 5 mutations, respectively. In comparison to TET2WT, TET2MTpatients were older in age, more likely to have dysplastic CMML, a higher number of co-occurring mutations, and lower-risk stratification. Importantly, TET2MTwere associated with a survival advantage (49 vs. 30 months, p< 0.0001), especially in the context of multiple TET2MT(≥2; 57 months, p< 0.001), and truncating TET2MT(51 months, p< 0.001). In addition, the adverse prognostic impact of ASXL1MTwas partially mitigated by concurrent TET2MT, with the ASXL1WT/TET2MTgenotype having better outcomes and resulting in further risk stratification of ASXL1inclusive CMML prognostic models, in comparison to ASXL1MTalone.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results